Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.

Xiang GuoShiliang WangAlex GodwoodDavid ClosePatricia C RyanLorin K RoskosWendy I White

Published in: International journal of rheumatic diseases (2018)

Our results revealed golimumab- and mavrilimumab-specific pharmacodynamic biomarkers, and demonstrated differential biomarker-treatment relationships in anti-TNF-IR and DMARD-IR patients, respectively. Early IL-6 change after anti-TNF antibody treatment may be a potential predictive biomarker for selection of different treatment regimens in anti-TNF-IR patients.

Keyphrases

rheumatoid arthritis
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
combination therapy
risk assessment
drug delivery
cerebrospinal fluid
replacement therapy